Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients

Junyan Zhu1,2, Fabian Trillsch1, Doris Mayr3, Christina Kuhn1, Martina Rahmeh1, Simone Hofmann1, Marianne Vogel1, Sven Mahner1, Udo Jeschke1 and Viktoria von Schönfeldt4

1Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
2Department of Obstetrics and Gynecology, Shanghai Jiao Tong University, School of Medicine, Renji Hospital, Shanghai, China
3Department of Pathology, University Hospital, LMU Munich, Munich, Germany
4Division of Gynecological Endocrinology and Reproductive Medicine, Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany

Correspondence to: Fabian Trillsch, email: Fabian.Trillsch@med.uni-muenchen.de
Keywords: prostaglandin receptor EP3; endometrial cancer; prognosis; estrogen receptor β; Ras
Received: May 23, 2017 Accepted: November 16, 2017 Published: December 09, 2017

ABSTRACT

Background: Prostaglandin E2 (PGE2) receptor 3 (EP3) regulates tumor cell proliferation, migration, and invasion in numerous cancers. The role of EP3 as a prognostic biomarker in endometrial cancer remains unclear. The primary aim of this study was to analyze the prognostic significance of EP3 expression in endometrial cancer.

Methods: We analyzed the EP3 expression of 140 endometrial carcinoma patients by immunohistochemistry. RL95-2 endometrial cancer cell line was chosen from four endometrial cancer cell lines (RL95-2, Ishikawa, HEC-1-A, and HEC-1-B) according to EP3 expression level. Treated with PGE2 and EP3 antagonist, RL95-2 cells were investigated by MTT, BrdU, and wound healing assay for functional assessment of EP3.

Results: EP3 staining differed significantly according to WHO tumor grading in both whole cohort (p = 0.01) and the subgroup of endometrioid carcinoma (p = 0.01). Patients with high EP3 expression in their respective tumors had impaired progression-free survival as well as overall survival in both cohorts above. EP3 expression in the overall cohort was identified as an independent prognostic marker for progression-free survival (HR 1.014, 95%CI 1.003-1.024, p = 0.01) when adjusted for age, stage, grading, and recurrence. Treatment with EP3 antagonists induced upregulation of estrogen receptor β and decreased activity of Ras and led to attenuated proliferation and migration of RL95-2 cells.

Conclusions: EP3 seems to play a crucial role in endometrial cancer progression. In the context of limited systemic treatment options for endometrial cancer, this explorative analysis identifies EP3 as a potential target for diagnostic workup and therapy.

INTRODUCTION

With about 320,000 new cancer cases in 2012, endometrial cancer (EC) becomes the fifth most common tumor, following breast, colorectum, cervix uteri, and lung cancer. It represents 4.8% of cancer in women worldwide and is the most frequent gynecological carcinoma in developed regions [1]. Moreover, the incidence rate in
USA is expected to increase from 19.1 per 10,000 in 2012 to 42.13 per 10,000 in 2030 [1, 2].

Obesity, nulliparity, late menopause, diabetes, and use of tamoxifen are the best-known risk factors of EC, which can be summarized into unopposed endogenous and exogenous estrogen [3]. Several prospective studies focusing on postmenopausal EC patients and healthy control women have demonstrated a notable positive correlation between circulation estradiol level and EC [4, 5]. Estrogen receptors (ER), mediating the effect of estrogen, play a key role in differentiation and invasion of EC [6].

In numerous cancers, chronic inflammation has been linked to tumor progression and was recently demonstrated for EC as well [7]. Risk reductions of EC have been associated with a high-frequency use of aspirin, a non-steroidal anti-inflammatory drug (NSAID), decreasing prostaglandin (PG) synthesis via inhibiting the activity of cyclooxygenases (COXs) [8], especially in obese women according to the latest meta-analysis [9]. COX2 mRNA, protein expression and prostaglandin E2 (PGE2) synthesis are notably elevated in EC compared to healthy endometrium [10, 11]. Moreover, PGE2 has been shown to promote proliferation and invasion in EC [12]. PGE2 exerts its biological actions via binding to its seven-transmembrane, G-protein coupled receptors (GPCRs), termed EP1, EP2, EP3, and EP4 [13]. EP3 is reported to regulate the cancerogenesis and progression in various cancer cells, such as human prostate [14], breast [15], liver [16], colon [17], oral cancer cells [18]. Although the uterus is one of the organs with most abundant EP3 [19], only little is known about the contribution of EP3 in EC so far [12].

The present study aimed to examine the EP3 expression in tissue samples of EC patients and its association with clinicopathologic characteristics and survival. Also, we tried to find the mechanism of EP3’s effect on EC using human EC cells and establish the rationale of PGE2’s tumor-promoting action in EC.

RESULTS

Patients characteristics

Detailed medical records of 140 EC patients including age, stage of disease, histology, and grading are listed in Table 1. The median follow-up was 82.71 months and during the follow-up period, 18 (12.9%) patients recurred and 36 (25.7%) died.

EP3 expression in EC and correlation with clinicopathological characteristics

EP3 staining showed significant difference within the World Health Organization (WHO) grading in the overall cohort (p = 0.011) (Figure 1A-1D) as well as in the endometrioid adenocarcinoma subgroup (p = 0.013) (Figure 1E). In the overall cohort, the highest expression was in G3 (median = 30%), while the lowest expression was in G1 (median = 5%, p = 0.013). G2 staining showed no statistical differences compared to either G1 or G3 staining. The expression in endometrioid adenocarcinoma group followed the same trend. G1 staining (median = 5%) was much weaker than G2 (median = 15%, p = 0.041) and G3 staining (median = 65%, p = 0.013) and no differences were found between G2 and G3 group. EP3 expression among the different histological subtypes exhibited decreasing density for from undifferentiated (median = 45.5%), over mucinous cancer (median = 45%), serous carcinoma (median = 30%), mixed cell (median = 10%), and endometrioid histology (median = 7.5%), although the differences were not significant (Figure 1F-1I).

Besides that, no significant differences in EP3 expression were noted between different International Federation of Gynecology and Obstetrics (FIGO) stages. The expression of EP3 comparing cases being negative vs. positive for lymph node involvement or relapse was also not significantly different.

Prognostic significance of EP3 in EC

A cut-off value of 72.5 was identified by using Receiver Operating Characteristic (ROC) curve. The staining percentage below 72.5 was defined as the low EP3 expression in 111 EC tissues (79.3%), while the one above 72.5 as the high EP3 expression was identified in 29 EC tissues (20.7%). Survival analysis was performed in the whole cohort as well as in specific subgroups such as FIGO I, endometrioid cancers, and FIGO I endometrioid cancers groups. Kaplan-Meier analysis indicated that patients with high expression in tumor had impaired progression-free survival (PFS) and overall survival (OS) in the overall cohort (10-year-PFS rate, 62.1% vs. 74.7%, p=0.046, Figure 2A, 10-year-OS rate, 64.7% vs. 78.1%, p=0.022, Figure 2B) as well as in FIGO I endometrioid cancer group (10-year-PFS rate, 70.2% vs. 81.8%, p=0.047, Figure 2C; 10-year-OS rate, 74.0% vs. 83.9%, p=0.041, Figure 2D). Neither OS nor PFS in other subgroups showed significant differences, which is most likely related to the limited number of cases and a low number of events. In order to evaluate whether EP3 immunostaining is an independent prognostic factor, multivariate analyses were conducted. The biomarker and clinicopathological variables which have a great impact on the regression coefficient of EP3 were involved in the analysis, including age, stage, grading, and recurrence. After adjusting for these factors, the expression of EP3 in the overall cohort was showed to be an independent prognostic marker for PFS (HR 1.014, 95%CI 1.003-1.024, p = 0.01) (Table 2) but not for OS (HR 1.008, 95%CI 0.998-1.019, p = 0.122). C-index for PFS was 0.855, indicating that the Cox model was capable of predicting the prognosis accurately [20, 21].
Correlations with other EC-related proteins

We performed a correlation analysis to evaluate the association of EP3 with proteins that are related to EC. The staining of EP3 showed no statistically significant correlation with ERα (correlation coefficient r = -0.15; p = 0.091), progesterone receptor A (PRA) (correlation coefficient r = -0.095; p = 0.286), PRB (correlation coefficient r = -0.023; p = 0.793), and glycodelin A (GdA) (correlation coefficient r = 0.153; p = 0.88). However, we found a significant negative correlation between EP3 and ERβ (correlation coefficient r = -0.225; p = 0.011) (Figure 3).

PGE2 enhances EP3 expression in EC cells

Available EC cell lines were analyzed for EP3 expression, identifying RL95-2 and HEC-1-A with
Figure 1: EP3 expression in EC tumor samples detected by immunohistochemistry. (A-C) Representative microphotographs of EP3 staining in different grading of EC tissue. (D, E) EP3 expression is associated with grading with weakest staining in G1 tumors in overall cohort and endometrioid tumor subgroup. *p < 0.05. (F-I) Representative microphotographs of EP3 staining in different histological subtypes of EC tissue. Scale bars equal 200 μm.

Figure 2: Kaplan-Meier analysis for EP3 in EC patients. Individuals with high EP3 expression exhibit impaired PFS and OS in both overall cohort (A, B) and FIGO I endometrioid cancer group (C, D) compared to those with low EP3 expression.
high and moderate levels of EP3 protein, respectively, compared to Ishikawa and HEC-1-B with low and undetectable EP3 expression levels (Supplementary Figure 2). According to these results, we chose RL95-2 cell line as the model for our functional EP3 study.

To confirm the effect of PGE2 on EP3, we examined both mRNA and protein levels of EP3 in RL95-2 cells after exposure to PGE2. Both EP3 mRNA and protein were noted to be increased following PGE2 treatment (Figure 4).

**Proliferation of EC cells is inhibited by EP3 antagonist**

After 48 hours of treatment with 10, 100, 1000 nM PGE2, the EP3 antagonist L-798,106 or the vehicle control (DMSO, 0.1%), MTT assay was used to assess viability. L-798,106 significantly decreased viability in a dose-dependent manner compared to control group, consistent with a pro-proliferative effect of EP3 (Figure 5A). Given that MTT assay is designed to measure the number of metabolically active cells, we conducted a BrdU assay, which assesses the proliferative cells by quantifying the BrdU incorporated into DNA during the S-phase [22]. Aligned with MTT, BrdU also indicated that EP3 antagonist inhibited the cells proliferation (Figure 5B). Contrarily, neither MTT nor BrdU showed a changed proliferation of RL95-2 following PGE2 treatment (Figure 5).

**Migration of EC cells is inhibited by EP3 antagonist**

To identify whether EP3 could facilitate metastasis of endometrial cells, we performed wound healing (scratch) assay. The results showed that after treatment of EP3 antagonist, the migration ability of RL95-2 cells was significantly suppressed compared to that in the vehicle group (Figure 6).

**Inhibited EP3 increases ERβ expression and decreases Ras activity in EC cells**

As immunohistochemistry showed a negative association of EP3 with ERβ, we further investigated whether EP3 acts upstream of ERβ. Both ERβ mRNA and protein were upregulated by L-798,106 treatment (Figure 7A, 7B). A previous study demonstrating that ERβ acts as a inhibitory signaling molecule upstream of Ras, prompted us to examine the activity of Ras in response to L-798,106 treatment [23]. As shown in Figure 7C, EP3 antagonist significantly decreased the activity of Ras in a time-dependent manner.

**EP3 does not change the estradiol biosynthesis**

Since EP3 can change the expression of ERβ, we speculated it might also have some effect on estradiol biosynthesis. According to a previous report, EC cell lines can form estradiol from estrone [24]. To verify our hypothesis, we estimated the estradiol concentration of EC cells exposed to L-798,106 together with 10% FBS, which contains estrone. Given that the conversion can be observed after 24 h incubation [24], we set the incubation time point as 24 h. However, EP3 antagonist did not affect the formation of estradiol (Supplementary Figure 3).

**DISCUSSION**

In this study of 140 EC tumor samples, we confirmed that EP3 is expressed in EC tissues and showed for the first time that EP3 expression in glandular epithelial cells correlates with tumor grade and is associated with impaired prognosis regarding PFS and OS. For EC, the results of our explorative analysis could show that EP3 might serve as a novel diagnostic and therapeutic target strongly deserving further investigation.

Furthermore, we demonstrated that EP3 might also play a role in regulating endometrial tumor growth.

---

**Table 2: Multivariate Cox regression analysis of all included patients regarding PFS (n=140)**

| Variable        | Coefficient | HR (95%CI)            | P Value |
|-----------------|-------------|-----------------------|---------|
| Age, y          | 0.038       | 1.039 (1.003-1.076)   | 0.036   |
| FIGO stage      | 1.038       | 2.824 (1.261-6.324)   | 0.012   |
| WHO grading     |             |                       | 0.426   |
| 1 vs. 2         | -0.284      | 0.753 (0.309-1.835)   | 0.533   |
| 1 vs. 3         | -0.604      | 0.546 (0.221-1.353)   | 0.192   |
| EP3             | 0.013       | 1.014 (1.003-1.024)   | 0.010   |
| Recurrence      | 2.957       | 19.240 (7.710-48.013) | <0.001  |

Significant results are shown in bold; HR: Hazard Ratio; CI: confidence interval.
In vitro, we could show that EP3 antagonist may attenuate proliferation and migration of EC cells, which supports the possible significance of EP3 in oncogenesis as previously reported. EP3 knockout mice have shown to markedly reduce tumor growth and tumor-associated angiogenesis [25]. By activating downstream signaling pathways, such as protein kinase A (PKA) [16], extracellular signal-regulated kinases 1 and 2 (ERK1/2) [26] and phosphoinositide 3-kinase (PI3K)/Protein Kinase B (AKT)/Glycogen synthase kinase 3 beta (GSK-3β) pathway [27], EP3 enhances the viability [16], proliferation [28], and invasiveness [15] of various cancer

Figure 3: Correlation analysis of EP3 and ERβ in EC tissue (n=128).

Figure 4: The effect of PGE2 on EP3 in RL-952 cells. (A) Cells treated either with vehicle (0.1% (v/v) DMSO) or 1μM PGE2 for 4h and subjected to RT-PCR. Bar graph represents mean ± SEM (n = 6). **p < 0.001 (compared to vehicle treated control group). (B) Cells treated either by vehicle (0.1% (v/v) DMSO) or 1μM PGE2 for 12h and subjected to western blotting. Histogram represents the ratio of EP3 to β-actin as assessed with pooled densitometric data. Data was normalized to the expression of vehicle treated group. β-actin was used as loading control. Bar graph represents mean ± SEM (n = 3). *p < 0.01 (compared to vehicle treated control group). For gel source data, see Supplementary Figure 4.
cells. Besides the direct influence on cancer cells, EP3 also promotes the tumor metastasis and angiogenesis by upregulating the matrix metalloproteinases (MMP)-9 of endothelial cells [29], which is an essential component of stroma and constitutes the tumor microenvironment. All these studies support our finding regarding the anti-cancer function of EP3 antagonist in EC cells.

In contrast to a previous report [12], our study did not confirm an effect of PGE2 on EC cells, even though PGE2 was proved to upregulate the expression of EP3 in our study. This might underlie the fact that aspirin instead of non-aspirin NSAIDs reduces the risk of EC [9]. Aspirin has been reported to regulate the growth of prostate cancer cells in a PGE2-independent way [14]. There might also be a PGE2-independent pathway in EC cells. Alternatively, the nonspecific binding of PGE2 to other receptors, such as EP2 and EP4, which have been known to increase cyclic adenosine monophosphate (cAMP) via Gs protein [13], might counteract the effect of EP3. This is the main reason we chose L-798,106, a highly selective antagonist of EP3 for our study to avoid interference caused by nonspecific binding. The same study showed EP3 did not influence proliferation of Ishikawa cell line [12]. These discrepancies about EP3 and PGE2 might be due to the usage of different cell lines as an experimental model. The Ishikawa cell line, used by the other group,

Figure 5: EP3 antagonist but not PGE2 suppresses proliferation of RL95-2 cells. (A) Cells cultured with indicated concentrations of PGE2 or L-798,106 for 48 h. The viability was determined by MTT assay. Results are normalized to cell viability of control group (0.1% (v/v) DMSO). Bar graphs represent mean ± SEM (n = 3). *p < 0.05 (compared to vehicle treated control group). (B) Cells treated with vehicle (0.1% (v/v) DMSO), 1μM PGE2 or 1μM L-798,106 for 48 h. Proliferation was determined by BrdU assay. Results were normalized to cell proliferation of control group. Bar graphs represent mean ± SEM (n = 6). *p < 0.01 (compared to vehicle treated control group).

Figure 6: EP3 antagonist inhibits migration ability of RL95-2 cells. (A) Representative images show cell migration into the wounded area in vehicle treated group and 1 μM L-798,106 treated group. (B) Histogram compares migration in vehicle treated group and 1 μM L-798,106 treated group. Results were normalized to cell proliferation of control group. Bar graph represents mean ± SEM (n = 4). *p < 0.05 (compared to vehicle treated control group).
barely expresses EP3 according to our data and thus could be less sensitive to EP3 pharmacological stimulation.

For the first time, we could show that EP3 was negatively associated with ERβ in EC tissue. Pharmacological research provides more information to verify that EP3 regulates ERβ, although the mechanism is far from clear. L-798,106 increased ERβ expression in RL95-2 cells. ERβ belongs to nuclear receptor superfamily and is clarified to be a modulator of ERα by functionally opposing it [30] and by repressing ERα transcriptional activity [31]. Although the effect of ERβ in EC has not been fully elucidated, accumulating evidence reveal that ERβ has a protective effect on the endometrium [32–34] and promotes differentiation and inhibits proliferation as well as invasion of endometrium [30, 35, 36]. In addition, ERβ is also shown to inhibit the migration of cancer cells [37].

Ras, a GTPase, transduces different downstream signalings by interacting with various Ras-effectors, such as Raf kinase, PI3K, and Ras guanine nucleotide exchange factors (Ral-GEFs) [38] and plays an important role in multistep carcinogenesis in EC [39, 40]. The activation of Ras can be induced by either mutant Ras or alteration of Ras protein expression. Here, we confirmed that EP3 antagonist decreased active Ras. Since ERβ can modulate Ras signaling [23], EP3 might regulate phenotypes of RL95-2 cells via ERβ/Ras.

As EP3 does not affect estradiol biosynthesis, the regulation of ERβ apparently was not induced by estradiol. The main effect of EP3 is to bind to the Gi protein and inhibit cAMP production [41], which is documented to increase the ERβ protein expression rather than ERα protein expression and promote ERβ transcriptional activation [42]. Therefore, EP3 might negatively regulate ERβ by adjusting the cAMP concentration.

Also, an inhibitory effect of EP3 on tumor development has been observed. In prostate and colon cancer, EP3 mRNA was remarkably reduced compared to corresponding normal tissue and EP3 impaired growth ability of these two cancer cell lines [14, 17]. Furthermore, EP3 was reported to inhibit the hormone-dependent growth of breast cancer by reducing aromatase activity of adipose stromal cells [43]. Among all the prostaglandin receptors, EP3 is the most complicated receptor because of its various isoforms. The human EP3 gene, consisting of ten exons and generating nine mRNAs, encodes at least eight distinct EP3 splice variants, encodes which is documented to increase the ERβ protein expression rather than ERα protein expression and promote ERβ transcriptional activation [42]. Therefore, EP3 might negatively regulate ERβ by adjusting the cAMP concentration.

Over the past years, molecular cancer biology has been integrated into the clinical routine of different tumor entities (e.g., breast cancer [49]). In this context, the Cancer Genome Atlas Research Network proposed a new classification of EC and categorized EC as POLE
ultramutated, microsatellite instability hypermutated, copy-number low, and copy-number high [50]. The four TGCA subtypes are related to different clinical outcomes, among which the copy-number high subgroup has impaired PFS, while the POLE ultramutated subgroup has improved PFS [50]. Mutations of RPL22 are almost exclusively identified in the microsatellite instability (MSI) group [50]. Direct sequencing of RPL22 exons 2 and 4 in 226 MSI endometrial tumors confirmed 51.6% tumors were heterozygous for the 43delA mutation, which was also presented in RL95-2 cell line [51]. Consequently, we speculate that this cell line could represent the MSI group, the survival of which is centered. Although not yet fully implemented in clinical routine, this classification gains more prognostic significance so that our results on EP3 will need to be confirmed in this context in future investigations.

In conclusion, we demonstrate for the first time that EP3 expression in glandular epithelial cells is associated with advanced WHO grading and poor patients’ prognosis. Inhibited EP3 mediates an anti-cancer effect in EC cells, which can be utilized for therapeutic interventions. As the results are partially contradictory to previous studies in other cell lines and tumor entities, our study indicates that EP3 seems to act in a cell and tissue type-specific manner. For EC, we could show that EP3 might serve as a novel diagnostic and therapeutic target strongly deserving further investigation.

MATERIALS AND METHODS

Patients

Formalin-fixed paraffin-embedded tissue of 140 patients, who received surgery for EC at the Department of Obstetrics and Gynecology of the Ludwig-Maximilians-University Munich between 1990 and 2002 was available. All patients provided informed consent before surgery. Staging and grading were assessed by two gynecological pathologists according to the criteria of FIGO and WHO. Follow-up data were obtained from the Munich Cancer Registry. PFS was defined as the time of operation to relapse or death from any cause, whereas OS was the time from diagnosis to the death or date of the last follow-up.

The study was performed according to the Declaration of Helsinki 1975. We used the remaining material of the tumor tissue after the initial histopathological diagnosis had been completed. The current study was approved by the Ethics Committee of the Ludwig Maximilians University, Munich, Germany (approval number 063-13). Authors were blinded for clinical information during experimental analysis.

Immunohistochemistry

Immunohistochemistry was performed as previously described by our lab [52]. Paraffin-embedded and formalin-fixed EC samples were incubation with the polyclonal rabbit IgG anti-EP3 antibody (Abcam), which was diluted at the ratio of 1:300, overnight. The signal was amplified with HRP-polymer (Zytochem-Plus HRP Polymer-kit, Zytomed, Berlin, Germany) for 30 min followed by incubating with diaminobenzidine (Dako, Hamburg, Germany) for 2.5 min. In the end, counterstaining with hematoxylin was carried out.

To support the validity of the EP3 staining, we used slides made from one normal colon tissue as the positive and negative control (Supplementary Figure 1). The negative control was performed by substituting for the primary antibody with a pre-immune serum (Rabbit Super Sensitive™ Negative Control, Hague, the Netherland).

The immunostaining of EP3 showed dots and an uneven distribution. The intensity of staining varied considerably within one slide. Therefore, the scoring was made according to the percentage of immunostained glands. The estimation of the percentage of EP3-positive glands was conducted by viewing the tumor area at 5x and 10x objectives and the results were recorded as an exact percentage. All slides were evaluated by two independent investigators. The staining and scoring with primary antibody ERα, ERβ, PRA, PRB, and GdA were performed as previously described by our research team [53, 54].

Cell culture and drugs

One well-differentiated cell line, Ishikawa and three moderate-differentiated cell lines, RL95-2, HEC-1-A, and HEC-1-B cells were purchased from European Collection of Cell Culture (ECACC, Salisbury, UK) and maintained in RPMI 1640 medium containing 10% fetal bovine serum (FBS, Thermo Fisher Scientific) without antibiotic at 37°C in a humidified 5% CO2 incubator. In each experiment, cells were seeded in wells overnight before being incubated with test substances or dimethyl sulfoxide (DMSO) unless otherwise indicated. PGE2, L-798,106, a highly selective EP3 antagonist, and EP3 agonist, sulprostone was purchased from Tocris Bioscience. The results of MTT and BrdU showed that the agonist we chose did not affect proliferation of EC cells. Although Abrahao et al. [55] and Fujino et al. [26] claimed sulprostone to be a selective EP3 agonist, it has been shown that sulprostone is an EP1/EP3 dual agonist [13, 48]. As other EP3 highly selective agonists such as ONA-AE-248 are currently not commercially available, we decided to concentrate on the antagonist L-798,106 to avoid interfering effects caused by non-specific binding.
**RNA isolation and reverse transcription**

Total RNA was obtained from cultured cells using a RNeasy Mini Kit (Qiagen, Hilden, Germany) and converted to cDNA with an MMLV Reverse Transcriptase First-Strand cDNA synthesis kit (epicentre, madison, WI, USA) as instructed by the manufacturer.

**Quantitative real-time RT-PCR**

20 μL reaction mixture containing 1 μL TaqMan® Gene Expression Assay 20 x (Applied Biosystems, target PTGER3, Nr. Hs00168755_m1, target ESR2, Nr. Hs01100353_m1, target ACTB, Nr. Hs99999903_m1), 10 μL TaqMan® Fast Universal PCR Master Mix 2 x (Applied Biosystems), 1 μL cDNA template and 8 μL RNase-free water was prepared per probe on an Optical Fast 96-well plate (Applied Biosystems) and covered by an optical adhesive film. PCR assays were run by using Applied Biosystems 7500 Fast Real-time PCR system. Enzymes activation was performed at 95°C for 20 s on hold. Afterward, 40 cycles of qPCR denaturing at 95°C for 3 s and annealing at 60°C for 30 s were run. The comparative CT method, also referred to as the ∆∆CT method was applied for the results. For ∆CT values calculation, β-actin was used as an endogenous control. The results are representative of at least three independent experiments.

**Western blotting and Ras-GTP assay**

The procedure and protocol of western blotting were previously described by our group [56]. Briefly, cell lysates were electrohoresed by SDS-PAGE and transferred to PVDF membranes. The membranes were incubated overnight with 1:2000 dilution of EP3 antibody (ab117998, Abcam), 1:200 dilution of ERβ antibody (53472, Anaspec) or 1:1000 dilution of β-actin antibody (A5441, Sigma). Afterwards, membranes were washed and incubated for 1 h with 1:1000 dilution of the corresponding alkaline phosphatase-conjugated secondary antibodies. Blotting was detected and visualized by BCIP/NBT Color Development Substrate (Promega). GTP-bound RAS was determined using the active Ras detection kit (8821, Cell Signaling) according to the manufacturer’s instruction. Images were analyzed by an image analyzer (Molecular Imager® Gel DocTM XR+, Bio-rad) using software Quantity One 4.6.7 (Bio-Rad, Munich, Germany). β-actin was used as an endogenous control (Supplementary Figure 4).

**Cell viability assay**

RL95-2 cells were seeded at the density of 1.5 × 10⁴ cells/well in 96-well plates in sextuplicate. The next morning cells were incubated with different concentration of PGE2 or L-798,106 for 48 h. 5 mg/mL MTT [3-(4,5-dimethylthiaoly)-2,5-diphenyltetrazolium bromide] (Sigma) in phosphate-buffered saline (PBS) was prepared. 20 μg MTT solution was added to each well for 1.5 h at 37°C. The culture medium along with MTT was then removed. 200 μL DMSO was added to each well to dissolve the visible formazan crystals, followed by mixed thoroughly on the shaker for 5 min at room temperature. The optical density (OD) was read at 595 nm using Elx800 universal Microplate Reader.

**Cell proliferation assay**

RL95-2 Cells were seeded in 96-well plates at 5 × 10³ cells/well in sextuplicate. The next morning cells were incubated with different concentration of PGE2 or sulprostone for 48 h. 5-Bromo-2’-Deoxyuridine (BrdU) incorporation assay (11647229001, Roche) was used to determine the cell proliferation according to manufacturer’s protocols. OD was quantified at 450 nm using Elx800 universal Microplate Reader.

**Wound healing (scratch) assay**

1.4 × 10⁶/well RL95-2 cells were cultured in 24-well-plates overnight. The next morning the central fields of confluent monolayers were scratched with a 200 μl pipette tip to make artificial wound gaps. The detached cells were aspirated and rinsed once with PBS. 1 μM L-798,106 was added to treat cells. After 0 h, 24 h, cell migration was monitored by photographing using an inverse phase contrast microscope (Leica Dmi1, Leica, Wetzlar, Germany) with a camera (LEICA MC120 HD, Leica, Wetzlar, Germany). Photomicrographs of wounded areas covered by cells were analyzed by software Image J (http://rsb.info.nih.gov/ij). The cell migration area = area at 0 h – area at 24 h.

**Estradiol measurements**

3 × 10⁵/well RL95-2 cells were seeded in 24-well-plates. After treated with 1 μM L-798,106 for 24 hours, the supernatant was collected and centrifuged (13,200 g, 10 min) to remove cell debris. The estradiol concentration was subsequently determined using chemiluminescent immunometric assay (IMMULITE 2000 immunoassay system) (Siemens, Germany) as described by the manufacturer.

**Statistical analysis**

A Student’s t-test (two-tailed) was used to analyze means of two groups. Mann-Whitney U or Kruskal-Wallis tests were conducted to compare non-parametric variables between or among groups. A Spearman rank test was performed for correlations between continuous variables. Survival times were compared using Kaplan-Meier (log-rank) test method. The ROC curve was
drawn to identify an appropriate cut-off. The ROC curve analysis is one of the most widespread methods used in cut-off point selection. The ROC curve is a plot, y-axis of which represents sensitivity and x-axis of which represents (1-specificity) [57]. Youdan index, defined as the maximum (sensitivity+specificity-1) [58], is applied to ensure the optimal cut-off which can maximize the sum of sensitivity and specificity [59, 60]. A cox-regression model for multivariate analyses was used. Harrell’s c-index was performed to evaluate the accuracy of the Cox model using R 3.3.1 with Hmisc and rms packages (http://www.r-project.org). A p-value below 0.05 was considered statistically significant for all analyses. The data were analyzed using the Statistical Product for Social Science (SPSS, IBM, Armonk, NY, USA) version 23.0.

ACKNOWLEDGMENTS

We thank China Scholarship Council for awarding Junyan Zhu a scholarship. The sponsors did not participate in study design, data analysis, and writing the manuscript. Also, we would like to show our gratitude to Eileen Deuster for proofreading.

CONFLICTS OF INTEREST

All authors declare no conflicts of interest with this study.

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359-386.
2. Sheikh MA, Althouse AD, Freese KE, Soisson S, Edwards RP, Welburn S, Sukumvanich P, Comerci J, Kelley J, LaPorte RE, Linkov F. USA endometrial cancer projections to 2030: should we be concerned? Future Oncol. 2014; 10:2561-2568.
3. Morice P, Leary C, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016; 387:1094-1108.
4. Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, Krogh V, Lenner P, Shore RE, Biessy C, Muti P, Riboli E, Koenig KL, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer. 2004; 108:425-432.
5. Audet-Walsh E, Lepine J, Gregoire J, Plante M, Caron P, Tetu B, Ayotte P, Brisson J, Villeneuve L, Belanger A, Guillemette C. Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. J Clin Endocrinol Metab. 2011; 96:E330-339.
6. Yu CG, Jiang XY, Li B, Gan L, Huang JF. Expression of ER, PR, C-erbB-2 and Ki-67 in endometrial carcinoma and their relationships with the clinicopathological features. Asian Pac J Cancer Prev. 2015; 16:6789-6794.
7. Dossus L, Rinaldi S, Becker S, Lukanova A, Tjonneland A, Olsen A, Stegger J, Overvad K, Chabbert-Buffet N, Jimenez-Corona A, Clavel-Chapelon F, Rohrmann S, Teucher B, et al. Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer. 2010; 17:1007-1019.
8. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010; 10:181-193.
9. Verdoordt F, Friis S, Dehlerendoff C, Albieri V, Kjaer SK. Non-steroidal anti-inflammatory drug use and risk of endometrial cancer: a systematic review and meta-analysis of observational studies. Gynecol Oncol. 2016; 140:352-358.
10. Jarzabek K, Koda M, Walentowicz-Sadlecka M, Grabiec M, Laudanski P, Wolczynski S. Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type I endometrial cancer biology. Tumour Biol. 2013; 34:4007-4016.
11. Willman EA, Collins WP, Clayton SG. Studies in the involvement of prostaglandins in uterine symptomatology and pathology. Br J Obstet Gynaecol. 1976; 83:337-341.
12. Ke J, Yang Y, Che Q, Jiang F, Wang H, Chen Z, Zhu M, Tong H, Zhang H, Yan X, Wang X, Wang F, Liu Y, et al. Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer. Tumour Biol. 2016; 37:12203-12211.
13. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999; 79:1193-1226.
14. Kashiwagi E, Shiota M, Yokomizo A, Isumi M, Inokuchi J, Uchiyumi T, Naito S. Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells. Endocr Relat Cancer. 2013; 20:431-441.
15. Kang JH, Song KH, Jeong KC, Kim S, Choi C, Lee CH, Oh SH. Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer. 2011; 11:334.
16. Ma J, Chen M, Xia SK, Shu W, Guo Y, Wang YH, Xu Y, Bai XM, Zhang L, Zhang H, Zhang M, Wang YP, Leng J. Prostaglandin E2 promotes liver cancer cell growth by the upregulation of FUSE-binding protein 1 expression. Int J Oncol. 2013; 42:1093-1104.
17. Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T, Sugimoto Y, Negishi M, Narumiya S, Sugimura T, Wakabayashi K. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut. 2004; 53:1151-1158.
18. Hoshikawa H, Goto R, Mori T, Mitani T, Mori N. Expression of prostaglandin E2 receptors in oral squamous cell carcinomas and growth inhibitory effects of an EP3
selective antagonist, ONO-AE3-240. Int J Oncol. 2009; 34:847-852.
19. Kotani M, Tanaka I, Ogawa Y, Usui T, Mori K, Ichikawa A, Narumiya S, Yoshimi T, Nakao K. Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol Pharmacol. 1995; 48:869-879.
20. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982; 247:2543-2546.
21. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15:361-387.
22. Porstmann T, Ternynck T, Avrameas S. Quantitation of 5-bromo-2-deoxyuridine incorporation into DNA: an enzyme immunoassay for the assessment of the lymphoid cell proliferative response. J Immunol. Methods. 1985; 82:169-179.
23. Niklos F, Thomas C, Rajapaksa G, Bado I, Gustafsson JA. ERbeta regulates NSCLC phenotypes by controlling oncogenic RAS signaling. Mol Cancer Res. 2014; 12:843-854.
24. Hevir-Kene N, Rizner TL. The endometrial cancer cell lines Ishikawa and HEC-1A, and the control cell line HIEEC, differ in expression of estrogen biosynthetic and metabolic genes, and in androstenedione and estrone-sulfate metabolism. Chem Biol Interact. 2015; 234:309-319.
25. Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, Kobayashi M, Satoh K, Narita M, Sugimoto Y, Murata T, Yoshimura H, Narumiya S, Majima M. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med. 2003; 197:221-232.
26. Fujino T, Toyomura K, Chen XB, Regan JW, Murayama T. Prostaglandin E(2) regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells. Biochem Pharmacol. 2011; 81:379-387.
27. Du M, Shi F, Zhang H, Xia S, Zhang M, Ma J, Bai X, Zhang L, Wang Y, Cheng S, Yang Q, Leng J. Prostaglandin E2 promotes human cholangiocarcinoma cell proliferation, migration and invasion through the upregulation of beta-catenin expression via EP3-4 receptor. Oncol Rep. 2015; 34:715-726.
28. Loffler I, Grun M, Bohmer FD, Rubio I. Role of cAMP in the promotion of colorectal cancer cell growth by prostaglandin E2. BMC Cancer. 2008; 8:380.
29. Amano H, Ito Y, Suzuki T, Kato S, Matsui Y, Ogawa F, Murata T, Sugimoto Y, Senior R, Kitasato H, Hayashi I, Satoh Y, Narumiya S, Majima M. Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis. Cancer Sci. 2009; 100:2318-2324.
30. Weihsa Z, Saji S, Makinen S, Cheng G, Jensen EV, Warner M, Gustafsson JA. Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc Natl Acad Sci U S A. 2000; 97:5936-5941.
31. Hall JM, McDonnell DP. The estrogen receptor beta isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology. 1999; 140:5566-5578.
32. Paul M, Cholewa K, Mazurek U, Witek A, Wilczok T. Estrogen receptor beta delta 6 (ER beta delta 6) isoform in human endometrial hyperplasia and adenocarcinoma. Cancer Invest. 2004; 22:211-218.
33. Smuc T, Rizner TL. Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol. 2009; 301:74-82.
34. Hong-Bing C, Yu-Feng Z, Bi-Cheng W, Ling-Ling G. Expression of estrogen receptors α and β protein in endometrial carcinoma. Cancer Ther. 2008; 6:907-911.
35. Fatima I, Saxena R, Kharkwal G, Hussain MK, Yadav N, Hajela K,ankwar PL, Dwivedi A. The anti-proliferative effect of 2-[piperidinoethoxyphenyl]-3-[4-hydroxyphenyl]-2H-benzo(b) pyran is potentiated via induction of estrogen receptor beta and p21 in human endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol. 2013; 138:123-131.
36. Wada-Hiraike O, Hiraite H, Okinaga H, Imamov O, Barros RP, Morani A, Omoto Y, Warner M, Gustafsson JA. Role of estrogen receptor beta in uterine stroma and epithelium: insights from estrogen receptor beta−/− mice. Proc Natl Acad Sci U S A. 2006; 103:18350-18355.
37. Ma L, Liu Y, Geng C, Qi X, Jiang J. Estrogen receptor beta inhibits estradiol-induced proliferation and migration of MCF-7 cells through regulation of mitofusin 2. Int J Oncol. 2013; 42:1993-2000.
38. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 2000; 10:147-154.
39. Fujimoto J, Ichigo S, Horii M, Morishita S, Tamaya T. Estrogen induces c-Ha-ras expression via activation of tyrosine kinase in uterine endometrial fibroblasts and cancer cells. J Steroid Biochem Mol Biol. 1995; 55:23-31.
40. Albright CD, Tsongalis GJ, Resau JH, Kaufman DG. Human endometrial carcinoma cells release factors which inhibit the growth of normal epithelial cells in culture. Cell Biol Toxicol. 1995; 11:251-261.
41. An S, Yang J, So SW, Zeng L, Goetzl EJ. Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce
both intracellular calcium and cAMP signals. Biochemistry. 1994; 33:14496-14502.

42. Coleman KM, Dutertre M, El-Gharbawy A, Rowan BG, Weigel NL, Smith CL. Mechanistic differences in the activation of estrogen receptor-alpha (ER alpha)- and ER beta-dependent gene expression by cAMP signaling pathway(s). J Biol Chem. 2003; 278:12834-12845.

43. Richards JA, Brueggemeier RW. Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J Clin Endocrinol Metab. 2003; 88:2810-2816.

44. Kotani M, Tanaka I, Ogawa Y, Usui T, Tamura N, Mori K, Narumiya S, Yoshimi T, Nakao K. Structural organization of the human prostaglandin EP3 receptor subtype gene (PTGER3). Genomics. 1997; 40:425-434.

45. Yang J, Xia M, Goetzl EJ, An S. Cloning and expression of the EP3-subtype of human receptors for prostaglandin E2. Biochem Biophys Res Commun. 1994; 198:999-1006.

46. Kotani M, Tanaka I, Ogawa Y, Suganami T, Matsumoto T, Muro S, Yamamoto Y, Sugawara A, Yoshimasa Y, Sagawa N, Narumiya S, Nakao K. Multiple signal transduction pathways through two prostaglandin E receptor EP3 subtype isoforms expressed in human uterus. J Clin Endocrinol Metab. 2000; 85:4315-4322.

47. Namba T, Sugimoto Y, Negishi M, Irie A, Ushikubi F, Kakizuka A, Ito S, Ichikawa A, Narumiya S. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature. 1993; 365:166-170.

48. Tamma G, Wiesner B, Furkert J, Hahn D, Oksche A, Schaefer M, Valenti G, Rosenthal W, Klussmann E. The prostaglandin E2 analogue sulprostone antagonizes vasopressin-induced antidiuresis through activation of Rho. J Cell Sci. 2003; 116:3285-3294.

49. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490:61-70.

50. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, et al, and Cancer Genome Atlas Research Network; Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497:67-73.

51. Novetsky AP, Zighelboim I, Thompson DM Jr, Powell MA, Mutch DG, Goodfellow PJ. Frequent mutations in the RPL22 gene and its clinical and functional implications. Gynecol Oncol. 2013; 128:470-474.

52. Scholz C, Heubelirn S, Lenhard M, Friese K, Mayr D, Jeschke U. Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients. BMC Res Notes. 2012; 5:551.

53. Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, Jeschke U, Friese K, Mylonas I. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer. 2007; 43:2434-2444.

54. Lenhard M, Heubelirn S, Kunert-Keil C, Vrekoussis T, Lomba I, Ditsch N, Mayr D, Friese K, Jeschke U. Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer. BMC Cancer. 2013; 13:616.

55. Abrahao AC, Castilho RM, Squarize CH, Molinolo AA, dos Santos-Pinto D Jr, Gutkind JS. A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. Oral Oncol. 2010; 46:880-887.

56. Heubelirn S, Vrekoussis T, Etzl R, Rotzoll D, Kuhn C, Faigle G, Navrozoglou I, Stefos T, Makrigiannakis A, Jeschke U. Alpha tocopherol transfer protein (alphaTTP) is expressed in endometrial carcinoma and is correlated with FIGO stage and 5-year survival. J Cancer Res Clin Oncol. 2017; 143:773-781.

57. Nakas CT, Alonzo TA, Yiannoutsos CT. Accuracy and cutoff point selection in three-class classification problems using a generalization of the Youden index. Stat Med. 2010; 29:2946-2955.

58. Youden WJ. Index for rating diagnostic tests. Cancer. 1950; 3:32-35.

59. Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutoffpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol. 2006; 163:670-675.

60. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J. 2005; 47:458-472.